Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Reporting Period: Preliminary financial data provided for the year ended December 31, 2025. The filing also details operational and regulatory events occurring in March 2026.
Key Financial Metrics
The following figures are preliminary estimates for the year ended December 31, 2025, and have not been audited:
- Cash Position: Approximately $50.9 million in cash, cash equivalents, and restricted cash as of December 31, 2025.
- Total Revenue: Approximately $2.0 million.
- Product Revenue: Approximately $1.4 million.
- Unit Sales: 61 units of Symvess®.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, operating margins, or specific debt obligations.
Material Changes and Operational Updates
- ATM Suspension: On March 19, 2026, the Company suspended and terminated its ATM Prospectus (dated December 16, 2025) with TD Securities (USA) LLC, which allowed for the sale of up to $60 million of common stock. No further sales will occur under this agreement until a new prospectus is filed.
- Saudi Arabia Commitment: On March 4, 2026, the Company received a binding minimum purchase commitment of approximately $1.48 million for Symvess acellular tissue engineered vessels (ATEV) in the Kingdom of Saudi Arabia (KSA) for surgeon education and hospital evaluation. This is concurrent with negotiations for a joint venture and commercialization license, with an exclusivity period through July 2, 2026.
- Israel Regulatory Filing: On March 16, 2026, the Company filed a Marketing Authorization Application (MAA) with the Ministry of Health of the State of Israel for Symvess for the vascular trauma indication.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The Company is pursuing methods to make Symvess available on a hospital-by-hospital basis in Israel prior to MAA approval. Management emphasizes that the preliminary financial estimates are not a substitute for GAAP financial statements and should not be viewed as indicative of future results. The Company has updated its risk factors, which are incorporated by reference.
Risks and Contingencies: Forward-looking statements regarding commercialization timelines, regulatory approvals, manufacturing capacity, and reimbursement are subject to significant risks and uncertainties. The finalization of the KSA joint venture and license terms remains subject to further negotiation and execution of definitive agreements.
Investor Verification Checklist
- Verify the final audited financial statements for the year ended December 31, 2025, to confirm the preliminary revenue and cash estimates.
- Monitor the status of the new prospectus filing required to reactivate the ATM facility for capital raises.
- Track the execution of definitive agreements for the KSA joint venture and the finalization of the $1.48 million purchase commitment.
- Review the updated Risk Factors (Exhibit 99.2) for specific changes to the Company's risk profile.
- Confirm the timeline for the Israel MAA approval and the progress of hospital-by-hospital availability.